{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"EVENET","nct_id":"NCT06472388","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=evenet-nct06472388. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"EVENET","arms":[{"description":"oral everolimus 5 mg/daily continuously until progression or intolerance or consent withdrawal. dose reduction for toxicity is allowed.","label":"Everolimus 5","type":"EXPERIMENTAL"},{"description":"oral everolimus 10 mg/daily continuously until progression or intolerance or consent withdrawal. dose reduction for toxicity is allowed.","label":"Everolimus 10","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Neuroendocrine Tumors","Progression","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2","Neuroendocrine Tumor of Pancreas","Neuroendocrine Tumor of the Lung","Neuroendocrine Tumor Carcinoid"],"enrollment":{"count":100,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Everolimus 5 MG","type":"DRUG"}],"last_update":"2024-06-25","lead_sponsor":"AC Camargo Cancer Center","official_title":"Randomized Phase II Trial of Everolimus 5 mg vs 10 mg/Daily for Patients With Advanced Neuroendocrine Tumors","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-05-20","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival rate at 12 months","timeFrame":"12 months"}],"references":[],"start_date":{"date":"2024-04-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors","url":"https://clinicaltrials.gov/study/NCT06472388"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/evenet-nct06472388"}